Clinical Scorecard: A Prognostic Model Utilizing LDH for Patients with Extensive-Stage Small-Cell Lung Cancer Undergoing Chemo-Immunotherapy and Consolidative Thoracic Radiation

At a Glance

Key Highlights

• Serum LDH is an independent prognostic marker for overall survival in ES-SCLC.
• Elevated LDH levels (>250 U/L) correlate with significantly reduced overall survival.
• A prognostic nomogram incorporating LDH, AJCC stage, SII, and immunotherapy status was developed.
• The nomogram demonstrated moderate discriminative ability for predicting overall survival at 12 and 24 months.
• High systemic immune-inflammation index (SII) is associated with worse outcomes in ES-SCLC.

Guideline-Based Recommendations

Diagnosis

• Utilize serum LDH levels as a prognostic indicator in ES-SCLC.

Management

• Consider integrating LDH levels into treatment decision-making for personalized management.

Monitoring & Follow-up

• Monitor LDH levels as part of routine assessment in patients undergoing treatment.

Risks

• Patients with elevated LDH levels face a higher risk of poor overall survival.

Patient & Prescribing Data

Patients diagnosed with extensive-stage small-cell lung cancer (AJCC stage III-IV).

Chemo-immunotherapy followed by consolidative thoracic radiotherapy is the standard treatment approach.

Clinical Best Practices

• Incorporate LDH and SII into prognostic assessments for ES-SCLC patients.
• Utilize the developed nomogram for risk stratification and management planning.

Related Resources & Content

• Prognostic significance of LDH in cancer
• Impact of immune checkpoint inhibitors in ES-SCLC
• Systemic immune-inflammation index in lung cancer